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Abstract
Background: The Hypertrophic Cardiomyopathy Registry (HCMR) is a NHLBI-funded, 
prospective registry of 2755 patients with HCM recruited from 44 sites in 6 countries.
Objectives: To improve risk prediction in HCM by incorporating cardiovascular magnetic 
resonance (CMR), genetic, and biomarker data.
Methods: Demographic and echocardiographic data were collected. Patients underwent CMR 
including cine imaging, late gadolinium enhancement imaging (LGE, replacement fibrosis) and T1 
mapping for measurement of extracellular volume (ECV) as a measure of interstitial fibrosis. 
Blood was drawn for biomarker (N-terminal pro brain natriuretic peptide [NTproBNP] and high 
sensitivity troponin T [cTnT]) and genetic analysis.
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Results: 2,755 patients were studied. Mean age was 49±11 years, 71% were male, and 17% non-
white. Mean ESC risk score was 2.48±0.56. Eighteen % had a resting left ventricular outflow tract 
(LVOT) gradient ≥30mmHg. Thirty six percent had a sarcomere mutation identified and 50 
percent had any LGE. Sarcomere mutation (+) patients were more likely to have reverse septal 
curvature morphology, LGE, and no significant resting LVOT obstruction. Those that were 
sarcomere mutation (−), had isolated basal septal hypertrophy, less LGE, and more LVOT 
obstruction. Interstitial fibrosis was present in segments both with and without LGE. Serum 
NTproBNP and cTnT levels correlated with increasing LGE and ECV in a graded fashion.
Conclusions: The HCMR population has characteristics of low risk HCM. 93% had no or only 
mild functional limitation. Baseline data separated patients broadly into 2 categories. One group 
was sarcomere mutation (+), more likely had reverse septal curvature morphology, more fibrosis, 
but less resting obstruction whereas the other was sarcomere mutation (−), more likely had 
isolated basal septal hypertrophy with obstruction but less fibrosis. Further follow-up will allow 
better understanding of these subgroups and development of an improved risk prediction model 
incorporating all these markers.
Condensed Abstract
HCMR is a prospective registry of 2755 hypertrophic cardiomyopathy patients from 44 sites in 6 
countries. Patients underwent cardiovascular magnetic resonance including cine imaging, late 
gadolinium enhancement imaging (LGE), and T1 mapping for measurement of extracellular 
volume and had blood drawn for biomarkers and genetics. Patients with sarcomere mutations more 
commonly had LGE and reverse septal curvature morphology but less resting outflow obstruction. 
Serum biomarkers correlated with the extent of LGE and ECV. Further follow-up will allow 
development of a useful risk prediction model incorporating these markers.
Keywords
Hypertrophic cardiomyopathy; Cardiovascular magnetic resonance; Biomarkers; Fibrosis; Late 
gadolinium enhancement
Introduction
The Hypertrophic Cardiomyopathy Registry (HCMR) is a prospective NHLBI-funded 
registry of 2755 HCM patients recruited across Europe and North America(1). The primary 
goal of the study is to improve risk prediction for important adverse clinical outcomes in 
HCM by integrating cardiovascular magnetic resonance (CMR) imaging, biomarker, and 
genetic data with standard clinical and echocardiographic findings. Insights gained by 
HCMR will directly impact patient care by providing a systematic evidence base to inform 
and advance management guidelines (2) and develop predictive models.(3) In current 
practice, risk stratification for sudden cardiac death (SCD) remains poorly resolved, 
particularly for patients at low and intermediate risk, limiting optimal utilization of 
implantable-cardioverter defibrillators (ICD’s).(4,5) In addition, models have not yet been 
developed to predict other key adverse outcomes such as incident heart failure or atrial 
fibrillation.
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Previous large cohorts of HCM patients were gathered retrospectively and/or from one or a 
handful of specialist centers (5–7) and, in general, CMR has not been systematically 
included.(5,7) An ongoing registry in 69 centers from 18 European countries is collecting 
patients with HCM (n=1739), but also includes other non-ischemic cardiomyopathies, and is 
only collecting variables acquired at the discretion of the clinical sites.(8) For example, only 
34% of patients in the latter registry underwent CMR, 46% had genetic testing, and 
biomarkers were not routinely collected.(8) HCMR is the first large prospective registry to 
include rigorous CMR imaging, genetic testing and prospective collection of blood for 
biomarker analysis.
Myocardial fibrosis measured by CMR has gained attention as a potential determinant of 
risk in patients with HCM. The presence of substantial late gadolinium enhancement (LGE), 
a marker of replacement fibrosis, has been associated with a 2-fold increase in SCD risk (6) 
and 3-fold increase in composite events(9) if present in >15% of LV mass. A meta-analysis 
of nearly 3000 patients from several studies demonstrated that the presence of LGE was 
associated with a 3.4 fold increased risk of SCD/ICD discharge and 1.8 fold increase in all-
cause mortality(10). The extent of LGE was also associated with an increased risk of 
SCD/ICD discharge (1.36/10% LGE, p=0.005) in a continuous fashion. A recent study 
suggests that adding LGE to American College of Cardiology (ACCF)/American Heart 
Association (AHA) risk stratification, along with apical aneurysm morphology and multiple 
runs of NSVT improved identification of indications for ICD placement.(11) Interstitial 
rather than replacement fibrosis may be an additional risk marker in HCM(12). HCMR is the 
first large multicenter study to use T1 mapping to assess extracellular volume as a surrogate 
for interstitial fibrosis in HCM. Integrating these markers of fibrosis and other CMR findings 
with clinical information, echocardiography, genotyping and biomarker analysis may further 
inform risk prediction in HCM. Baseline characteristics of 2755 patients with HCM are 
presented in the present manuscript.
Methods
The study design for HCMR has been previously published(1); the relevant methods are 
summarized here. HCMR is a prospective observational study. After written informed 
consent, all patients underwent standard clinical evaluation, CMR, and had blood drawn for 
genetic and biomarker analysis. Longitudinal follow-up is being conducted to determine the 
incidence of cardiovascular events, adjudicated by a clinical events committee.
Inclusion/Exclusion Criteria
Patients included were ages 18–65 with an established diagnosis of HCM defined as 
unexplained LVH (wall thickness >15mm) without cavity dilatation or known predisposing 
cause (uncontrolled hypertension, aortic stenosis, etc.)(2). Patients known to have other 
causes of infiltrative/hypertrophic cardiomyopathies such as amyloidosis, sarcoidosis, Fabry 
disease, Danon disease, or Noonan’s syndrome, or discovered to have these diagnoses 
through HCMR genotyping, were excluded. Patients older than 65 were excluded as they 
have high competing mortality risks, in particular from coronary artery disease and cancer.
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Additional exclusion criteria were 1) prior septal myectomy or alcohol septal ablation, 2) 
prior myocardial infarction or known CAD 3) incessant ventricular arrhythmias, 4) inability 
to lie flat, 5) contraindication to contrast-enhanced CMR including pacemakers, 
defibrillators, intraocular metal, certain types of intracranial aneurysm clips, severe 
claustrophobia, and Stage IV/V chronic kidney disease, 6) diabetes mellitus with end organ 
damage, 7) ongoing pregnancy, or 8) inability to provide informed consent.
Patient Enrollment
Patients were enrolled from 44 sites in the U.S. (18), Canada (4), United Kingdom (13), 
Italy (4), Germany (3), and the Netherlands (2) between April, 2014 and April, 2017 
(Supplemental Table 1). Participating sites are experienced centers with focused care of 
HCM patients as well as state-of-the-art CMR capabilities. Emphasis was placed on 
recruiting HCM patients across the risk spectrum including higher-risk patients referred for 
subsequent ICD implantation. Data regarding baseline demographics and clinical variables 
were recorded from clinical records including data from clinically-performed 
echocardiographic, Holter and exercise testing studies closest to the time of enrollment. ESC 
risk score was calculated using baseline clinical and echocardiographic data(3).
CMR methods
CMR was performed at 1.5 or 3 Tesla (T) on MR systems from the 3 primary vendors 
(General Electric, Philips Medical Systems, Siemens Healthineers) using a standardized 
protocol and multi-channel channel phased-array chest coils and electrocardiographic (ECG) 
gating. After rapid localization of the heart, short axis cine steady state free precession 
imaging (SSFP) was performed covering the whole heart in 8mm thick slices (no gap). 
Typical cine SSFP parameters included TR/TE 3.1/1.2 msec, in-plane resolution of 2–2.5 
mm, temporal resolution of 40–50 msec. Baseline T1 mapping was performed in 3 short axis 
slices centered in the mid LV, representing 16 of the 17 AHA segments in the nearly 80% of 
the sites that had appropriate software. The Shortened Modified Look-Locker Inversion 
recovery technique (ShMOLLI), using a 5(1)1(1)1 Look-Locker scheme with conditional 
image processing (13), was used as the recommended standard on Philips and Siemens 
systems, both for native and post-contrast T1 mapping acquisitions. Gadolinium contrast 
was administered intravenously as a bolus dose of 0.15 mmol/kg. Long-axis function by 
SSFP cine imaging was then obtained. Post-contrast T1 mapping acquisitions were 
performed in the same 3 short axis slices as pre-contrast, starting at 5, 14, and 29 minutes 
post-contrast. LGE imaging was acquired in the same long axis and short-axis stack 
locations beginning at minute 17 post-contrast with a 2D breath-hold, segmented inversion-
recovery sequence (inversion time (TI) optimized by the Look-Locker sequence (TI scout) to 
null normal myocardium). Total imaging time was approximately 60 minutes.
CMR Image Analysis—Commercially available software (MedisSuite 3.0 and 
QMassMR, Medis Inc., Leiden, NL) was used for analysis of all CMR images (cine, T1 
maps, and LGE) in a core laboratory. LV mass, volumes, wall thickness and thickening was 
measured according to SCMR standards.(14) Cine images in short-axis contiguous cuts were 
evaluated for LV and RV volumes and myocardial mass by manually tracing endocardial and 
epicardial borders. Papillary muscles were included in LV volumes and excluded from LV 
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mass. Cine images were also evaluated for morphology(15) and defined as 1) localized basal 
septal hypertrophy 2) reverse curvature septal hypertrophy 3) apical HCM 4) concentric 
HCM 5) mid-cavity obstruction with apical aneurysm or 6) other, i.e. did not fit into the 
preceding 5 categories (Figure 1).(16) Cine images in 2- and 4-chamber long-axis cuts were 
evaluated for left atrial volumes using the bi-plane area-length method, at end-ventricular 
systole, before atrial contraction, and end-ventricular diastole.(17)
Quantification of LGE was performed according to SCMR standards(14) using both the 6 
S.D. quantitative threshold as well as visually.(18) LGE was categorized as none, >0–5%, 
>5–10%, >10–15% and >15% of LV mass. T1 quantification was performed on a segmental 
basis by non-linear least-squares fitting of the segmental inversion recovery curves, resulting 
in multiple T1 measurements (one pre- and 3 post-contrast) calculated. Gadolinium partition 
coefficient λ was calculated segmentally and globally by linear regression of pre and post-
contrast R1 (=1/T1) relaxation rates in myocardium, against the corresponding R1’s in the 
blood pool of the same short axis slice. The linear regression slope was converted to 
extracellular volume (ECV) using the patient’s fractional blood volume of distribution (1-
hematocrit).(19) ECV index was calculated as ECV (%) times LV mass.
Genetics
Amplicon-based sequencing for 36 cardiomyopathy-associated genes was undertaken using 
the Illumina MiSeq platform. Bioinformatic analysis was performed using the Genome 
Analysis Toolkit version 4 best practice guidelines. Variants were visually confirmed 
through inspection of BAM files. Variant annotation was performed using SNPEff (http://
snpeff.sourceforge.net) and Ensembl’s Variant Effect Predictor (VEP version 95). Data from 
publicly available resources (ClinVar (version 20190211) and gnomAD r2.1) and the Oxford 
Regional Genetics Laboratory in-house mutation database was used to inform variant 
classification. Following quality control, 2,636 individuals (99.1%) were deemed suitable for 
subsequent genetic analyses.
Serum Biomarkers
Blood samples were transported on ice, processed within 60 minutes of phlebotomy to 
obtain serum and EDTA-anticoagulated plasma, aliquoted, and stored at −70°C until they 
were batched tested at the end of the study period in the Biomarker Research and Clinical 
Trials Laboratory at Brigham and Womeńs Hospital. Cardiac troponin T (cTnT) was tested 
using the Roche (Roche Diagnostics Corporation, Indianapolis, IN) TnT STAT Gen 5 assay 
to assess for myocardial injury (19,20). The analytical measurement range (AMR) for the 
assay is 6–10000 ng/L and coefficients of variation were 4.1% at 15.6 ng/L, 4.0% at 27.6 
ng/L and 2.5% at 1893 ng/L. The N-terminal fragment of the propeptide of B-type 
natriuretic peptide (NT-proBNP) was measured using the Roche proBNP II assay to assess 
hemodynamic or myocardial wall stress. AMR of the assay is 5–35,000 pg/mL and total 
imprecision of the assay was 2.5% at both 138 pg/mL and 4578 pg/mL.
Data Management and Statistical Analysis
Clinical data were entered in an on-line data management system. Upon entry, data 
underwent a series of range and quality checks. Baseline arrhythmias were defined as a 
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history of nonsustained ventricular tachycardia and/or atrial fibrillation. Summary statistics 
for continuous variables include mean ± standard deviation, and/or median and interquartile 
range. Most data were non-normally distributed, so the nonparametric Kruskal-Wallis rank 
test was used to compare independent groups. The exceptions were age and BMI where t-
tests or analysis of variance were used. Categorical variables are summarized by number and 
percent of valid (non-missing) values and analyzed by contingency table analysis (chi-
square). Odds ratios were calculated for 2 × 2 tables. Where multiple comparisons were 
made within tables, Bonferroni corrections were used to control Type I error rate.(20) The 
association of morphology categories with demographic and clinical variables was assessed 
by contingency table analysis (chi-square) for categorical variables and one-way analysis of 
variance for continuous variables. Savage Scores test was used to compare LGE distribution 
by morphology categories in a singly ordered (LGE) contingency table analysis.(21) 
Statistical testing was performed with Stata, v15 (Stata Corp., College Station, TX) and 
StatXact 7 (Cytel, Inc., Cambridge, MA).
Results
Baseline Demographics
Number of patients enrolled at each site is shown in Supplemental Table 1. Of 2762 patients 
initially enrolled, 1362 were enrolled in North America and 1400 in Europe. Seven patients 
were subsequently excluded as they were demonstrated to be phenocopies genetically and 
not have HCM, leaving 2755 for analysis. Baseline demographic and clinical information 
are shown in Table 1.
Echocardiography
Mean maximal wall thickness was 18.6±4.8 mm. Eighteen % of participants had a peak 
gradient>30 mm Hg and these patients’ average gradient was 69±31. Fifty-nine % had mitral 
regurgitation and 12% were graded as moderate or severe. Mean pulmonary artery pressure 
was 28±11 mm Hg. Maximum left atrial dimension was 4.2±0.8 cm.
Holter Monitoring and Exercise Testing
Among 1672 patients who had undergone clinically-performed 24 hour Holter monitoring, 
AF was seen in 4% and nonsustained ventricular tachycardia in 12%. The 1520 participants 
who underwent clinically-performed exercise treadmill testing achieved 9.7 METS on 
average and 12% had a hypotensive response to exercise or failed to increase systolic blood 
pressure by 20mm Hg.
CMR Cine Data
A total of 2651 patients completed the CMR as 38 (1.4%) had studies aborted due to 
claustrophobia and 52 (2%) for other reasons. The contrast dose used was 0.15 mM/kg 
(mean 20±9 ml). The rhythm at the time of the CMR was normal sinus in 93%, atrial 
fibrillation in 2 % and other, e.g. PVC’s, bigeminy, etc., in 5%. LV and RV structure and 
function results derived from SSFP cine CMR images are shown in Table 2 and examples 
are shown in Figure 1.
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There were 2628 studies available for morphologic evaluation with the remaining 36 
incomplete for morphologic assessment. 1197 (46%) had isolated basal septal hypertrophy, 
1059 (38%) reverse septal curvature, 224 (8%) apical HCM, 36 (1%) concentric HCM, 79 
(3%) mid-cavity obstruction with apical aneurysm, and 33 (1%) were classified as other. 
Demographic and clinical characteristics associated with specific morphologies are 
presented in Table 3. Patients with reverse septal curvature morphology were, in general, 
younger, had lower BMI, more likely minority, had thicker walls, more arrhythmias, less 
hypertension, and less LVOT obstruction as compared to those with isolated basal septal 
curvature.
Maximal LV wall thickness of any segment was 20.6±4.8 mm. Results comparing maximal 
LV wall thickness by baseline variables are presented in Supplemental Table 2. Significant 
relationships with wall thickness were found for age, BMI, male gender, LVOT gradient≥30 
mm Hg, and sarcomere mutation (+). Left atrial width from the 3-chamber long axis view 
was 4.8±0.8 cm. Left atrial area from the 4-chamber long axis view was 28.9±7.6 cm2.
Myocardial fibrosis
Of 2755 patients, 254 (92%) had valid LGE values to allow assessment of replacement 
fibrosis. LGE was present in 50% of patients based on visual criteria, Central Illustration, 
and in 60% based on >6 standard deviation signal criteria. In the 50% of patients who had 
LGE by visual analysis, mean LGE mass was 3.7±5.2% of LV mass. In patients with LGE 
present, ESC risk score was higher than those without LGE (2.61±0.59 vs. 2.33±0.49, 
p<0.001). Only 2% of patients (n=46) had LGE>15% of LV mass. Morphologic correlates of 
LGE are shown in Table 4. A high percentage of patients with reverse septal curvature 
hypertrophy and apical aneurysm patterns had LGE whereas isolated basal septal 
hypertrophy demonstrated LGE less frequently than other morphologies. The reverse septal 
curvature pattern was associated with the majority (79%) of cases with >10% LGE.
Comparison of the presence of LGE with baseline variables is shown in Table 5. BMI, 
family history of HCM, maximal wall thickness, reduced LVEF, baseline arrhythmias, 
hypertension, and sarcomere mutation (+) were all significantly associated with LGE 
presence. Patients with a family history of HCM were 1.2 times more likely to have LGE 
present than those without. Patients with LVEF < 55% were nearly 1.3 times more likely to 
have LGE present. Patients with baseline arrhythmias were 1.4 times more likely to have 
LGE present and those with a sarcomere mutation were 1.8 times more likely to have LGE 
present than those without.
There were 2082 patients (76%) with analyzable native T1 and 2013 (73%) valid ECV 
measures. Mean native T1 of the entire LV myocardium was 972±74 at 1.5T and 1170±84 at 
3T. Native T1 in segments without LGE was 969±74 at 1.5T and 1157±86 at 3T compared 
to 976±74 at 1.5T and 1179±81 at 3T (p<0.001 for both) in segments with LGE. There were 
no statistically significant differences in native T1 between the MR vendors. Pooled across 
field strengths, native T1 was 2% higher in females than males (p<0.001) and showed 
modest statistically significant correlations with LGE and wall thickness, but not with age.
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ECV was greater in regions with LGE (0.30±0.05) than those without (0.28±0.04, p<0.001). 
Mean ECV was greater in females (0.31±0.04) than in males (0.28±0.04, p<0.001). For 
comparison purposes, ECV in normal volunteers ranges between 0.25–0.28 and tends to rise 
with age and be higher in females (22,23). Patients with higher ECV had smaller BMI, less 
likely to have a family history of HCM, had greater wall thickness, more baseline 
arrhythmias, and were more likely to have a sarcomere mutation (Table 6). When evaluated 
by morphology, ECV was lowest in isolated basal septal hypertrophy compared to reverse 
septal curvature, apical and mid-cavity obstruction subtypes (Supplemental Table 3). ECV 
index, a measure of mass of interstitium, was 49.2±20.2g.
HCM Risk Factors
The mean ESC risk score (3) was 2.48±0.56, suggesting that the study group is low risk. Of 
the enhanced ACCF/AHA risk factors(11), 12% had a family history of SCD, 13% had a 
history of syncope, 9% had sustained or nonsustained VT, 4% had wall thickness >30mm, 
2% had >15% LGE, and 3% had an apical aneurysm.
Genetics
DNA samples were obtained from 2,661 individuals. Genetic analyses for genes that can be 
reliably interpreted in HCM comprise: the core sarcomeric genes (MYH7, MYBPC3, 
TNNT2, TNNI3, MYL2, MYL3, ACTC1 and TPM1) and the well-established ‘phenocopy’ 
genes (GLA, PRKAG2, LAMP2 and TTR). Overall, 29.5% (n=774) of individuals were 
found to have a variant classified as “pathogenic” or “likely pathogenic” in a sarcomere 
gene, with variants in the MYBPC3 (18.5%) and MYH7 (8.0%) genes accounting for the 
majority. Only 3 individuals (0.11%) demonstrated a combination of two likely pathogenic 
or pathogenic variants in confirmed sarcomere genes. Seven individuals were found to 
harbor pathogenic variants within either GLA (n=4) or TTR (n=3), indicating a diagnosis of 
Fabry’s disease or hereditary amyloidosis respectively; these individuals were removed all 
subsequent phenotypic analyses. In 12.3% (n=325) of individuals, “variants of uncertain 
significance (VUS)” were detected in the sarcomere genes. See Supplemental Material for 
the approach to VUS. Using this approach, based on gene-specific interpretations, we 
dichotomized the HCMR cohort into individuals carrying a sarcomere variant, i.e. 
‘sarcomere mutation positive’ (n=943; 35.8%) and those who did not, i.e. ‘sarcomere 
mutation negative’ (n=1693; 64.2%). Using this dichotomous criterion, just under 1% of 
probands carried 2 sarcomere variants (and none >2).
Those who were sarcomere mutation (+) were younger, had a lower BMI, more often female 
and white, had a family history of HCM, and had less hypertension, Table 7, consistent with 
prior findings.(24) However, they also were less likely to have a significant LVOT gradient 
which may, in part, reflect differences in morphology as more of the sarcomere mutation (+) 
demonstrated reverse curvature asymmetric septal hypertrophy (58.1%) relative to isolated 
basal septal hypertrophy (33.8%), ratios that were reversed in the sarcomere mutation (−) 
group (30.7% and 51.8%, respectively), p<0.0001. In addition, fewer sarcomere mutation 
(+) individuals demonstrated apical hypertrophy (4.5% vs. 10.7%), concentric hypertrophy 
(0.2% vs. 2.0%), and “other” forms of hypertrophy (0.8% vs, 1.6%). Incidence of mid-cavity 
obstruction was similar (2.6% vs. 3.2%). LVEF was similar between groups. Sarcomere 
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mutation (+) patients were much more likely to have any LGE as well as more extensive 
LGE (Table 8). Native T1 was higher at 1.5T in sarcomere mutation (+) individuals (978±76 
vs. 968±74, p<0.02), but similar at 3T (1175±89 and 1167±81, respectively, p=0.21), likely 
due to lower n at 3T and thus lower power.
Biomarkers
NTproBNP and cTnT were obtained in 2,665 (97%) of the 2,755 patients in the HCMR 
analysis database. Supplemental Table 4 presents comparisons of demographic and clinical 
variables and NTproBNP. Because of the extreme skewness of the NTproBNP distribution, 
medians and IQR are presented as well as means and standard deviations. Increasing age 
was associated with increasing NTproBNP. Females had higher values than males as 
expected, obese patients had lower levels, and patients with baseline arrhythmias had higher 
levels. Patients with a resting LVOT gradient ≥30mm Hg and those with a reduced LVEF 
had higher values. NTproBNP levels increased as maximal wall thickness increased. The 
relationship between NTproBNP and categories of LGE is presented in Figure 2 (Left 
panel). A similar relationship was seen with increasing ECV (by quartile). (Supplemental 
Figure 1) NTproBNP was significantly higher in sarcomere mutation (+) than (−) individuals 
(594±842 vs. 520±1073, p < 0.001).
Normal values for cTnT for males were ≤ 22 ng/L and ≤14 ng/L for females (per Roche 
Diagnostics Corporation). Of the 2665 patients with valid values, 282 males (15%) and 186 
females (24%) had elevated cTnT. Supplemental Table 5 presents comparisons of 
demographic and imaging data and cTnT, abnormal vs. normal. Females were over 1.6 times 
more likely to have abnormal cTnT levels than males. Those with a history of hypertension 
were 1.3 times more likely to have abnormal cTnT levels and those with LVEF<55% were 
over 2.2 times more likely to have abnormal values. Minorities were 1.6 times more likely to 
have abnormal values and patients with baseline arrhythmias 1.7 times more likely. As 
maximal wall thickness increased, so did abnormal cTnT. The relationship between cTnT 
and categories of LGE is presented in Figure 2 (Right panel). In both genders, there was a 
stepwise increase in cTnT with categories of increasing LGE. A similar relationship was 
seen with increasing ECV (by quartile), although only in males. (Supplemental Figure 2) 
The incidence of elevated cTnT was similar in sarcomere mutation (+) and (−) groups (18% 
and 17%, respectively). NTproBNP was higher in sarcomere (+) than (−) groups (594±842 
vs. 520±1073, respectively, p<0.001).
Discussion
HCMR is the largest systematic, prospective natural history study in HCM to date which 
includes comprehensive CMR data in addition to other clinical metrics, genotyping, and 
biomarker analysis. Prior and ongoing registries are retrospective in nature and/or do not 
include systematic acquisition of these data.(5–7) The 2755 patients participating in HCMR 
reflect a broad sampling of North American and European sites and 17% minority 
enrollment. A third had a family history of HCM and a third had hypertension. Eighteen % 
of patients had a LVOT gradient ≥30mm Hg. Only 12% of patients had moderate or more 
mitral regurgitation. A sarcomere variant carrier yield of 35.8% is comparable to that seen 
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for HCM in usual routine diagnostic service laboratories, confirming that the case 
population on which HCMR is based is representative of ‘real world’ HCM practice. Based 
on the ESC risk scores, the patient group is of low risk.
The major contribution of the present study lies in the CMR, genetic, and biomarker findings 
and their inter-relationships in this population. Two relatively distinct populations were 
identified in HCMR. (Central Illustration) One was sarcomere mutation (+), and more likely 
to demonstrate reverse septal curvature morphology, have more extensive LGE, but less 
resting LVOT obstruction. The second group was sarcomere mutation (−), and more likely to 
demonstrate isolated basal septal hypertrophy, with less LGE, but more LVOT obstruction. 
The first of these groups represents the Mendelian form of familial HCM whereas the 
second group presumably has multifactorial disease(25), as evidenced by the higher burden 
of causes of secondary LVH (hypertension, high BMI, male sex, and older age, etc.). The 
finding that significant resting outflow obstruction indicates a lower likelihood of the 
familial form of HCM was not suspected. It is also notable that apical HCM is also less 
likely to reflect sarcomeric HCM.
Myocardial replacement fibrosis is prevalent (50%), although the frequency of extensive 
LGE is less than that noted in the study by Chan et al(6), in which the 4 sites included were 
highly specialized referral centers. Patients with LGE had thicker walls, more baseline 
arrhythmias, and were more likely to be sarcomere mutation (+), in keeping with the concept 
of a higher burden of LGE in clearly identified genetic disease. One prior study of 82 
patients showed that the extent of LGE had an odds ratio of 2.1 to predict mutation-positive 
HCM.(26) The ESC risk score increases modestly with any LGE compared to no LGE. 
Whether the presence and/or extent of LGE improves risk stratification compared to the ESC 
risk score remains to be determined with longer follow-up. One recent study does suggest it 
adds to ACCF/AHA guidelines for identification of patients who subsequently require an 
ICD.(11)
The vast majority of patients in this study (86%) have a form of asymmetric septal 
hypertrophy, either isolated basal or reverse curvature. Patients with the reverse curvature 
form were younger, less commonly had hypertension, and were more likely sarcomere 
mutation (+). They represented most of the cases of >10% LGE, providing further data for a 
link between genetics, morphology, and fibrosis. Follow-up will test whether this 
morphologic subtype with its link to sarcomere mutation positivity and increased fibrosis is 
a risk factor for outcome events. The other morphologic subgroup with extensive LGE was 
the mid-cavity obstruction with apical aneurysm subtype, which has been shown to be 
associated with higher risk and adds to ACCF/AHA risk stratification.(11,27)
In the HCMR cohort, there was evidence of interstitial fibrosis indicated by the elevated 
mean ECV when compared to prior measurements using the same techniques in normal 
controls.(28,29) ECV was mildly elevated even in regions without LGE, suggesting that 
interstitial fibrosis is a characteristic of HCM. Similar to LGE, increased wall thickness, 
baseline arrhythmias, and sarcomere mutation positivity were associated with interstitial 
fibrosis. Unlike LGE, there was more interstitial fibrosis in females.
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The 2 biomarkers that were measured were both elevated in subsets of patients in this 
cohort. NTproBNP was elevated subsets with resting LVOT gradient≥30mm Hg, reduced 
LVEF, more baseline arrhythmias, and sarcomere mutation (+). CTnT was higher in 
minorities and patients with hypertension, LVOT gradient≥30 mm Hg, increased wall 
thickness, and reduced LVEF. Whether elevated biomarkers are predictive of worse outcome 
in HCM will only be clarified with further follow-up. This is an understudied area, 
especially for NTproBNP.(30) One smaller study in Japan demonstrated worse outcomes 
with increasing levels of troponin.(31) cTnT has been shown to improve risk prediction in 
women, but only in the setting of coronary heart disease.(30) Both biomarkers demonstrated 
stepwise increases in relationship to LGE extent and ECV. Since LGE extent is a marker of 
SCD/ICD discharge in HCM, it may be that elevated biomarkers are a synergistic risk 
marker with either or both replacement and interstitial fibrosis. This points to the importance 
of developing a multivariable model using all of these potential risk markers to predict 
outcome events once follow-up is long enough to allow sufficient numbers of events to 
occur.
Limitations
This cohort excluded patients with HCM who had prior invasive septal therapy or ICD 
placement. Although minority recruitment was less than planned, the overall numbers may 
allow analysis of subpopulation differences and will likely be hypothesis-generating. The 
echocardiographic data were derived from clinical echo reports and thus protocols were not 
standardized. Therefore, reporting of provoked obstruction was incomplete. Stress testing 
and Holter monitoring at entry were also not protocol-driven and thus were not performed in 
every patient. While the use of ECV reduces the impact of magnetic field choice for T1 
mapping, all T1 mapping techniques may be method and vendor-dependent.
Conclusions
The HCMR study population is characteristic of patients with low risk HCM by ESC risk 
score. 93% had no or only mild functional limitation. These patients have predominantly 
septal hypertrophy, 18% have resting LVOT gradient≥30mm Hg, and half have LGE. Over a 
third are sarcomere mutation (+). Interstitial fibrosis is prevalent even in segments without 
LGE. Serum biomarkers are elevated and relate to both replacement and interstitial fibrosis 
in a graded fashion. Two relatively distinct populations were identified. One group was 
sarcomere mutation (+) and more likely had reverse septal curvature morphology, more 
fibrosis, and less resting obstruction whereas the other was sarcomere mutation (−), and 
more likely had isolated basal septal hypertrophy with resting obstruction and less fibrosis. 
Further follow-up will allow development of a model inclusive of the demographic, clinical, 
echocardiographic, CMR, biomarker and genetic variables that best predict risk of major 
adverse cardiac events in HCM.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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CMR cardiovascular magnetic resonance
LGE late gadolinium enhancement
ECV extracellular volume
NTproBNP N-terminal pro-brain natriuretic peptide
cTnT high sensitivity troponin T
LVOT left ventricular outflow tract
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Competency in Medical Knowledge:
Patients with hypertrophic cardiomyopathy and a sarcomere mutation associated with 
reversed septal curvature, more extensive myocardial fibrosis, and less resting ventricular 
outflow tract obstruction, can be distinguished from others without this sarcomere 
mutation, who more often have isolated basal septal hypertrophy with less fibrosis and 
greater resting obstruction.
Translational Outlook:
Further analysis of this registry and other sources should facilitate patient-specific risk 
profiling based on demographic, echocardiographic, magnetic resonance imaging, 
genetic, and biomarker data to identify those at risk of heart failure, arrhythmias and 
other adverse outcomes, including mortality.
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Figure 1. Steady state free precession 4-chamber long axis cine images from individual patients 
with the 6 different morphologic subtypes of HCM.
The six subtypes shown are: 1) localized basal septal hypertrophy 2) reverse curvature septal 
hypertrophy 3) apical HCM 4) concentric HCM 5) mid-cavity obstruction with apical 
aneurysm or 6) other
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Figure 2. Relationship of biomarkers to increasing amounts of late gadolinium enhancement 
(LGE).
N-terminal pro-brain natriuretic peptide (NTproBNP) and high sensitivity troponin T (cTnT) 
were measured in each patient as was the extent of LGE as a % of left ventricular mass on 
cardiac magnetic resonance imaging. Left – Median NTproBNP showing increasing levels 
relative to patients with increasing amounts of LGE (P<0.001 for trend). Right – similar 
trend shown for cTnT (separated by gender due to different normal values) with p<0.001 for 
trend for both.
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Central Illustration. Hypertrophic Cardiomyopathy Registry: Overall design and Findings.
2,755 patients from 44 sites in 6 countries were recruited. Two relatively distinct populations 
were identified as depicted in the slide. Left: 4-chamber inversion recovery gradient echo 
LGE image in a patient with reverse curvature asymmetric septal hypertrophy. Patchy LGE 
is noted in mid-septum. Right: similar orientation and image type in a patient with reverse 
curvature asymmetric septal hypertrophy. No LGE is noted. One group was sarcomere 
mutation positive, and more likely had reverse septal curvature morphology, more fibrosis, 
and less obstruction whereas the other was sarcomere mutation negative, and more likely 
had isolated basal septal hypertrophy with obstruction and less fibrosis.
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Table 1.
Baseline characteristics of patients enrolled in HCMR.
Variable Summary statistic Valid n (%)
Age (years) 49 ± 11 2738 (99.4)
Male gender 1953 (71.3) 2740 (99.5)
Race / Ethnicity 2737 (99.3)
 White 2311 (84.4)
 Black 204 (7.4)
 Asian 205 (7.5)
 Other 18 (0.7)
 Hispanic 60 (2.2) 2739 (99.4)
BMI (kg/m2) 29.3 ± 5.7 2726 (98.9)
Family history of HCM 2722 (98.9)
 1st degree 600 (22.0)
 2nd degree 84 (3.1)
 Both 1st and 2nd 228 (8.4)
Comorbidities
 Hypertension 997 (36.6) 2726 (99.0)
 Type II diabetes mellitus 213 (7.8) 2726 (99.0)
 Current smoker 387 (14.2) 2724 (98.9)
NYHA 2692 (97.7)
 Class I 1792 (66.6)
 Class II 706 (26.2)
 Class III/IV 194 (7.2)
Other clinical history
 Syncope 361 (13.2) 2726 (98.9)
 Heart failure 142 (5.2) 2733 (98.9)
 Stroke 76 (2.8) 2733 (98.9)
 Nonsustained ventricular tachycardia 196 (12.0) 1633 (59.3)
Number of runs 3.2 ± 12.1
 Atrial fibrillation 2723 (98.8)
 Persistent 77 (2.8)
 Paroxysmal 244 (9.0)
Symptoms at enrollment
 Chest pain 893 (32.8) 2726 (98.9)
 Dyspnea 1184 (43.4) 2726 (98.9)
Medications at enrollment
 Beta blocker 1547 (57.0) 2714 (98.5)
 Calcium channel blocker 508 (18.7) 2714 (98.5)
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Variable Summary statistic Valid n (%)
 ACE/ARB 644 (23.7) 2714 (98.5)
 Disopyramide 84 (3.1) 2714 (98.5)
 Statins 741 (27.3) 2714 (98.5)
 Diuretic 314 (11.6) 2714 (98.5)
 Oral anticoagulant 251 (9.2) 2714 (98.5)
 Oral antiplatelet agent 431 (15.8) 2714 (98.5)
Summary statistics are mean ± 1 standard deviation for continuous variables; n (%) for categorical variables.
Summary statistics based on non-missing values (Valid n) of total analyzed: 2755
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Table 2.
LV and RV volumetric results.




LV mass index (g/m2)
 Males 89±27
 Females 77±25
Maximal wall thickness (mm) 20.6±4.8
LV end diastolic volume (ml) 171±41
LV end diastolic volume index 85±17
LV end systolic volume (ml) 63±26
LV end systolic volume index (ml/m2) 31±12
LV stroke volume (ml) 108±24
LV stroke volume index (ml/m2) 54±10
LV ejection fraction (%) 64±8
LV mass/EDV ratio 1.0±0.3
Cardiac output (L/min) 6.7±1.6
Cardiac index (L/min/m2) 3.3±0.7
RV mass (g) 36±12
RV mass index (g/m2) 18±5
RV end diastolic volume (ml) 152±39
RV end diastolic volume index (ml/m2) 75±16
RV end systolic volume (ml) 50±24
RV end systolic volume index (ml/m2) 24±11
RV stroke volume (ml) 102±24
RV stroke volume index (ml/m2) 51±11
RV ejection fraction (%) 68±10
Data are mean ± 1 Standard Deviation.
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Table 3.









Variable N=1199 N=1063 N=224 N=36 N=79 N=33
Age (years) 51.6±10.3*§ 47.1±12.0† 51.3±9.7§ 50.0±11.3 49.7±11.4 45.8±13.7 < 0.001
BMI (kg/m2) 29.8±5.5* 28.6±5.6 28.9±4.8 33.5±8.1‡*†^ 28.9±5.4 28.6±6.2 < 0.001
<Male 839 (70.1) 758 (71.5) 175 (78.1) 30 (83.3) 47 (59.5) 22 (66.7) 0.014
Minority 121 (10.1)*† 179 (16.9)† 75 (33.5) 11 (30.6)‡ 22 (27.9)‡ 4 (12.1) < 0.001
Maximal wall 
thickness (mm) 17.4±3.6 
* 20.0±5.2†§ 17.1±4.5 22.2±6.3‡†§ 19.6±6.0‡† 16.7±3.5 < 0.001
LVOT gradient ≥ 
30mm Hg 279 (30.4)
* 164 (20.8)† 7 (5.1)‡ 8 (33.3)† 13 (23.6)† 2 (7.4) < 0.001
Arrythmias 161 (13.5)*† 224 (21.3) 51 (22.9) 6 (17.1) 28 (35.4)‡* 6 (18.2) < 0.001
LVEF < 55% 145 (12.4) 168 (16.3) 20 (9.1) 11 (30.6)‡† 13 (16.7) 4 (12.1) 0.002
HTN 504 (42.2)* 309 (29.3) 81 (36.3) 16 (44.4) 31 (39.2) 14 (42.4) < 0.001
Data are mean ± 1 standard deviation for continuous variables; n (%) for categorical variables.
Percentages based on non-missing values.
For each variable, correction for Type I error was set at < 0.0055 (0.05/9). If the overall p value was <0.0055, pairwise comparisons between 
morphology categories were made at p < 0.0055.
*








p<0.0055 vs. isolated basal septal
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Table 4.












Isolated basal septal 767 (66.5%) 353 (30.6%) 25 (2.2%) 8 (0.7%) 0 (0.0%)
Reverse curvature septal 322 (31.4%) 498 (48.5%) 127 (12.4%) 36 (3.5%) 43 (4.2%)
Apical 116 (54.2%) 81 (37.8%) 15 (7.0%) 1 (0.5%) 1 (0.5%)
Concentric 19 (57.6%) 11 (33.3%) 0 (0.0%) 3 (9.1%) 0 (0.0%)
Apical aneurysm 25 (32.1%) 35 (44.9%) 13 (16.7%) 5 (6.4%) 0 (0.0%)
Other 16 (48.5%) 12 (36.4%) 2 (6.1%) 1 (3.0%) 2 (6.1%)
Data are n (%).
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Table 5.
Distribution of presence of LGE for selected baseline variables.
Variables LGE present Unadjusted p value Bonferroni adjusted p value
Age (years) 0.029 0.319
 ≤ 40 (n = 528) 286 (54.2)
 41–64 (n = 1944) 958 (49.3)
 ≥ 65 (n = 75) 32 (42.7)
BMI (kg/m2) 0.001 0.013
 ≤ 25 (n = 606) 338 (55.8)
 26–30 (n = 974) 489 (50.2)
 ≥ 31 (n = 969) 451 (46.5)
Gender 0.032 0.352
 Male (n = 1820) 937 (51.5)
 Female (n = 729) 341 (46.8)
Race 0.068 0.748
 Minority (n = 398) 183 (46.0)
 Non-minority (n = 2149) 1095 (51.0)
Family history of HCM < 0.001 < 0.001
 Yes (n = 870) 489 (56.2)
 No (n =1669) 781 (46.8)
LVOT gradient ≥ 30 Hg mm 0.036 0.396
 Yes (n = 455) 207 (45.5)
 No (n = 1433) 733 (51.2)
Maximal wall thickness (mm) < 0.001 < 0.001
 ≤ 20(n=1692) 727 (43.0)
 21–29 (n = 540) 381 (70.6)
 ≥ 30 (n = 64) 53 (82.8)
Arrhythmias < 0.001 < 0.001
 Yes (n = 460) 295 (64.1)
 No (n = 2080) 975 (46.9)
Hypertension < 0.001 < 0.001
 Yes (n = 929) 409 (44.0)
 No(n= 1613) 863 (53.5)
LVEF < 55% < 0.001 < 0.001
 Yes (n = 354) 216 (61.0)
 No (n = 2195) 1062 (48.4)
Sarcomere mutation < 0.001 < 0.001
 + (n = 878) 614 (69.9)
 − (n= 1575) 626 (39.8)
Data are n (%).
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p values are from chi-square distribution or Savage score test for singly ordered categories, and unadjusted for multiple testing.
A Bonferroni correction would require a p value of < 0.0045 to declare statistical significance at a nominal Type I error rate of 0.05 (0.05/11).
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Table 6.
Comparison of ECV by selected baseline variables.
Variables ECV Mean ± SD Unadjusted p value Bonferroni adjusted p value
Age (years) 0.391 1.000
 ≤ 40(n = 417) 0.29 ± 0.04
 41–64 (n = 1537) 0.29 ± 0.05
 ≥ 65 (n = 58) 0.30 ± 0.06
BMI (kg/m2) < 0.001 0.001
 ≤ 25 (n = 485) 0.30 ± 0.05
 26–30 (n = 772) 0.29 ± 0.04
 ≥ 31 (n = 752) 0.29 ± 0.05
Gender < 0.001 0.001
 Male (n= 1417) 0.28 ± 0.04
 Female (n = 596) 0.31 ± 0.04
Race 0.546 1.000
 Minority (n = 323) 0.29 ± 0.05
 Non-minority (n = 1689) 0.29 ± 0.05
Family history of HCM < 0.001 0.001
 Yes (n = 683) 0.29 ± 0.05
 No (n = 1322) 0.30 ± 0.05
LVOT gradient 0.178 1.000
 ≥ 30 mm Hg (n = 356) 0.29 ± 0.05
 < 30 mm Hg (n = 1103) 0.29 ± 0.05
Maximal wall thickness (mm) < 0.001 0.002
 ≤ 20 (n = 1337) 0.29 ± 0.04
 21–29 (n = 411) 0.30 ± 0.05
 ≥ 30 (n = 51) 0.31 ± 0.05
Arrhythmias < 0.001 0.002
 Yes (n = 368) 0.30 ± 0.05
 No (n = 1639) 0.29 ± 0.04
Hypertension 0.123 1.000
 Yes (n = 718) 0.29 ± 0.04
 No (n = 1289) 0.29 ± 0.05
LVEF < 55% 0.005 0.055
 Yes (n = 264) 0.30 ± 0.05
 No (n = 1712) 0.29 ± 0.04
Genetics < 0.001 0.001
Sarcomere mutation + (n = 706) 0.30 ± 0.05
Sarcomere mutation − (n = 1261) 0.29 ± 0.05
ECV data are mean ± 1 Standard Deviation.













Neubauer et al. Page 27
p values are from Kruskal-Wallis test and unadjusted for multiple testing. A Bonferroni correction would require a p value of < 0.0045 to declare 
statistical significance at a nominal Type I error rate of 0.05 (0.05/11).
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Table 7.
Demographic and clinical differences by genetic category.
Variable
Sarcomere mutation (+) 
% (n)
Sarcomere mutation (−) 
% (n) Unadjusted p value
Bonferroni adjusted p 
value
Age (years) 46.2 ± 12.0 51.3 ± 10.4 < 0.001 < 0.001
BMI (kg/m2) 28.2 ± 5.4 29.8 ± 5.6 < 0.001 < 0.001
Male 65.1 (611) 75.3 (1260) < 0.001 < 0.001
Minority 28.4 (116) 37.4 (823) 0.001 0.009
Family history of HCM 54.7 (511) 22.3 (371) < 0.001 < 0.001
LVOT gradient ≥30mm Hg 19.0 (130) 26.8 (335) < 0.001 < 0.001
Arrhythmias 38.1 (185) 35.4 (749) 0.255 1.000
Hypertension 21.3 (199) 45.1 (752) < 0.001 < 0.001
LVEF < 55% 14.2 (126) 14.2 (227) 0.983 1.000
Data are mean ± 1 Standard Deviation for continuous variables and n (%) for dichotomous variables. A Bonferroni correction for multiplicity was 
made for 9 variables for nominal Type I error rate of 0.05: p < 0.0055 (0.05/9).
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Table 8.
LGE categories by sarcomere mutation status.
Category (n) Sarcomere mutation (+) N (%) Sarcomere mutation (–)
No LGE (1213) 264 (30.1) 949 (60.3)
>0–5% (965) 458 (52.2) 507 (32.2)
>5–10% (177) 101 (11.5) 76 (4.8)
> 10–15% (53) 33 (3.8) 20 (1.3)
>15% (45) 22 (2.5) 23 (1.5)
Data are n (%).
LGE categories were not equally distributed for sarcomere + and − groups (p < 0.001).
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